Flex Pharma’s Positive Human NLC Study Selected For Presentation At American Academy of Neurology Annual Meeting
BOSTON--(BUSINESS WIRE)--Click to Tweet
Flex Pharma, Inc. (NASDAQ: FLKS) announced that results from its recently completed study in nocturnal leg cramps (NLC) will be presented later today at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, B.C., Canada. As one of only 14 abstracts selected for late-breaking presentations at the AAN annual meeting, the abstract titled, “Orally-administered TRPV1 and TRPA1 activators reduce Nocturnal Leg Cramps in a randomized, blinded, placebo-controlled, crossover human trial,” will be presented during the Emerging Science Session at 6:21p.m PDT, followed by a poster presentation from 6:30-7:15pm PDT.
Flex Pharma, Inc. (NASDAQ: FLKS) announced that results from its recently completed study in nocturnal leg cramps (NLC) will be presented later today at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, B.C., Canada. As one of only 14 abstracts selected for late-breaking presentations at the AAN annual meeting, the abstract titled, “Orally-administered TRPV1 and TRPA1 activators reduce Nocturnal Leg Cramps in a randomized, blinded, placebo-controlled, crossover human trial,” will be presented during the Emerging Science Session at 6:21p.m PDT, followed by a poster presentation from 6:30-7:15pm PDT.